Business Wire

ADVA

23.3.2021 09:02:12 CET | Business Wire | Press release

Share
Proximus harnesses ADVA synchronization solution for 5G network timing

ADVA (FSE: ADV) today announced that Proximus is leveraging its Oscilloquartz timing technology to synchronize Belgium’s largest open mobile network. The deployment enables Proximus to improve speed, coverage and reliability for millions of mobile users throughout Belgium, while also preparing its network for next-generation services. By deploying ADVA’s core grandmaster devices, access boundary clocks and its enhanced primary reference time clock (ePRTC) solution, the country’s incumbent telecommunications service provider is ensuring the levels of timing accuracy and resilience needed for 5G, broadcast and other time-sensitive services. The technology was implemented by ADVA’s partner Arcadiz Telecom, a leading provider of connectivity solutions across the Benelux region.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210323005060/en/

“By harnessing ADVA’s network timing innovation, we’re ensuring unprecedented levels of precision and reliability. This deployment is a core component of our 5G strategy. It means more value not only for our customers looking to access data-intensive applications and stream high-quality video wherever they are, but also for telco operators using our open network,” said Patrick Delcoigne, director, network engineering and operations, Proximus. “ADVA’s grandmaster clock and ePRC cesium technology empower us to meet key timing challenges. It enables highly accurate phase precision, enhanced stability and long-term protection from GNSS outages. Just as important, though, is the support of the ADVA and Arcadiz Telecom team. Their engineers have worked closely with us to ensure that the network meets all of our requirements.”

Proximus’s new nationwide synchronization network is built on the OSA 5440 , an ultra-stable timing solution optimized for deployment in core networks and the OSA 5412 family of cost-effective, mid-scale synchronization devices engineered for deployment in a wide range of locations. It’s anchored by the robust and proven OSA 3230B ePRC cesium clock installed in two central sites. This supports high levels of frequency stability compliant with the strictest ITU-T standards and, combined with the OSA 5440, ensures long-term stability of UTC time. The extended stability performance of ADVA’s ePRC provides immunity against GNSS outages – a crucial requirement for mission-critical applications that should not rely on satellite-based timing alone.

“For major mobile network operators like Proximus, our PTP grandmaster and boundary clocks and our ePRTC solution are the perfect tools. They enhance overall performance and deliver the precision timing necessary for 5G use cases. Our technology also enables other services such as broadcast networks to migrate to IP-based timing,” commented Jörg Urban, senior director, business development, Oscilloquartz, ADVA. “The OSA 5412 Series and OSA 5440 support a smooth and cost-effective migration to next-generation phase and frequency synchronization. And with our ePRTC solution providing robust backup for GNSS, Proximus’ mobile customers can be sure of high-quality, uninterrupted services with no loss of performance.”

“At Arcadiz Telecom, we know what it takes to build a network ready to support tomorrow’s services. With ADVA’s Oscilloquartz timing technology and the ongoing support and maintenance of our team, Proximus can be confident that its synchronization infrastructure delivers for today’s needs while being fully equipped for the future,” said Marc Vandeputte, CTO, Arcadiz Telecom. “When it comes to 5G connectivity, every nanosecond counts. That’s why the stringent accuracy and stability of ADVA’s technology is so important. It empowers Proximus to deliver enhanced speeds, coverage and quality to its mobile users. For Belgians, this deployment will enable a wide range of new experiences from instant access to video streams to immersive AR and VR experiences.”


About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .

About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we’re creating new opportunities for tomorrow’s networks. For more information, please visit us at www.oscilloquartz.com .

Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com

Social Media:

https://www.facebook.com/pages/ADVA-Optical-Networking/37630238931

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye